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Summary The expression of the c-erbB-2 mRNA in human embryonic lung fibroblasts, a gastric cancer cell
line, mature placenta, and 25 gastric cancer tissues was examined by using the polymerase chain reaction
following reverse transcription. This technique can be used to examine c-erbB-2 mRNA expression in a small
endoscopic biopsy specimen before surgery.
To examine the genetic alterations of early stage cancer or
the phenotypic changes is very important for the elucidation
of malignant transformation and prediction of prognosis.
The human c-erbB-2 proto-oncogene is identified based on
close sequence homology in the tyrosine kinase domain to
the v-erbB and EGF receptor (Coussens et al., 1985; Yama-
moto et al., 1985). Interestingly, c-erbB-2 gene amplification
has been predominantly detected in carcinomas of glandular
epithelial origin, including mammary (King et al., 1985),
salivary gland (Semba et al., 1985), gastric and colon
tumours (Yokota et al., 1986). Increased expression of this
proto-oncogene product has gained clinical interest from the
observation that amplification of this gene in breast car-
cinomas might be related to poor prognosis (Slamon et al.,
1987; Zhou et al., 1987). In addition, an immunohisto-
chemical study on paraffin embedded tissue has shown that
overexpression of the c-erbB-2 gene might be associated with
poor prognosis in breast (Berger et al., 1988), ovarian (Ber-
chuck et al., 1990), and gastric cancers (Yonemura et al.,
1991). However, there were no suitable techniques to
examine the genetic alteration of early stage cancer or
phenotypic change. Recently, analytical techniques for
mRNA expression have been developed by PCR following
reverse transcription (RT-PCR) (Rappolee et al., 1988;
Chelly et al., 1988; Kawasaki et al., 1988; Kashani-Sabet et
al., 1988). In this study, we could specifically detect the
expression of the c-erbB-2 gene derived from a small amount
of human gastric cancer specimens by RT-PCR, and found
this method was sensitive and quantitative enough for ana-
lysis of c-erbB-2 gene expression of gastric cancer patients
before surgery.
Materials and methods
Specific oligonucleotide primers for c-erbB-2 amplification
were selected from the phosphorylation domain, containing
extensive differences in length and primary structure between
members of the human EGF receptor-related gene such as
the EGF receptor gene and the c-erbB-3 gene (Kraus et al.,
1989; Plowman et al., 1990). The P-actin mRNA chosen as
an internal control was also transcribed and amplified. The
sence c-erbB-2 primer, ERB-2 (5'-GATGTATTTGATGGT-
GACCT-3') corresponds to the c-erbB-2 cDNA sequence
(3424-3443), ERB-3 (5'-ATCTGGCTGGTTCACATATT-3')
represents the anti-sense strand of the c-erbB-2 cDNA
sequence (3587-3606). The sence P-actin primer P-ACT-4 (5'-
ATCACCATTGGCAATGAGCG-3') corresponds to the P-
actin cDNA sequence (2233-2252). ,3-ACT-5 (5'-TTGAAG-
GTAGTTTCGTGGAT-3') represents the anti-sense strand
of the P-actin cDNA sequence (2406-2425). With the use of
oppositely oriented primers, the 183 bp region ofthe c-erbB-2
gene or 93 bp region of the P-actin gene was amplified,
flanked by the 2 oligomers. ERB-1 (5'-ACCCCAGCCCTC-
TACAGCGGTACAGTGAGG-3') corresponding to c-erbB-
2 cDNA (3488-3517) or 13-ACT-6 (5'-TGAGGCACTCTTC-
CAGCCTT-3') corresponding to P-actin cDNA (2265-2284)
was used as the probe to detect the amplified c-erbB-2 or
P-actin PCR products. Total RNA was extracted from
human embryonic lung (HEL) fibroblasts, human gastric
cancer cells (MKN-7), human gastric cancer tissues, and
mature human placenta as described previously (Chomczyn-
ski & Sacci, 1987).
A precise dilution series of the template RNA was pre-
pared using yeast RNA to adjust the total to 1 jig. One jig of
each total RNA from HEL, MKN-7, placenta and gastric
carcinoma tissues was denatured by heated 95°C for 5 min
and chilled on ice. Each sample was incubated in a total
volume of 20 jil reaction mixture consisting of 1 x ampli-
fication buffer [10 mM Tris-HCI (pH 8.3), 50 mM KCI,
1.5mM MgC92, 0.01% gelatin, 0.05% Tween 20], 125 giM of
each dNTP (dATP, dCTP, dGTP, dTTP), 5 mM dithioth-
reitol, four units of RNasin (Promega Biotec, Madison, WI),
one unit of avian myeloblastosis virus reverse transcriptase,
and 50 pmol of the anti-sense primer. After 10 min ofincuba-
tion at room temperature, reverse transcription was allowed
to proceed at 42°C for 60 min. Then the samples was heated
to 95°C for 5 min to inactivate reverse transcriptase. After
cDNA synthesis, the reaction mixture was diluted with 80IlI
of 1 x amplification buffer, followed by addition of 225ftmol
of each dNTP, 50 pmol of each sense and anti-sense primer,
and 2.5 units of Taq polymerase (Perkin Elmer Cetus, Nor-
walk, CT). Each sample was amplified by 25 cycles of PCR;
each cycle consisted of a 1 min denaturation at 94'C, fol-
lowed by 2 min of annealing (48°C), and 2 min of extension
(72'C) steps. The PCR product was electrophoresed on a gel
of 2.0% agarose. The gel was photographed, and the PCR
product was transferred to a nylon membrane filter and
hybridised overnight to a 32P-end-labelled probe specific for
the target cDNA fragment. The autoradiogram was exposed
for 4-5 h with two intensifying screens at - 80°C. One fg
RNA of each sample as negative control was tested by
reverse transcription without reverse transcriptase and PCR
amplification.
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Results and discussion
First, the PCR amplified products from serial dilutions of
HEL and MKN-7 total RNA were analysed by Southern
blotting (Figures la and b). In addition, a duplicate PCR
assay ofeach RNA sample omitting reverse transcriptase was
run to confirm that the hybridisation signal was the result
from RNA and not DNA specific amplification. These results
in Figure 1 indicate that the PCR products amplified with the
primers, ERB-2 and ERB-3, could be detected at the concen-
tration of 3 4' g (12 ng) to HEL total RNA. On the other
hand, the PCR products from MKN-7 was detectable even at
10-4fg (100 pg) of total RNA. The same sample did not
produce any PCR-amplified fragments in the absence of
reverse transcriptase. Radioactivity of PCR products hybri-
dised with specific probes was measured by a Fujix Bio-
Image analyser (Fuji Photo Film Co., Ltd., Tokyo). The
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amount of radioactivity was plotted against the template
concentration (Figure 2). The PCR products were accumu-
lated linearly to the template concentration. The amplified
rates of MKN-7 and HEL were identical within the exponen-
tial phase of the PCR and that demonstrated the precise
measurement of this method. Comparison of the hybridisa-
tion signal intensities between HEL and MKN-7 suggested
that c-erbB-2 mRNA was overexpressed 72.6-fold in MKN-7
relative to HEL. However, the expression level of the P-actin
mRNA between MKN-7 and HEL was the same.
Second, total RNA from six cases of surgically resected
gastric cancer tissues and mature placenta were tested by the
RT-PCR assay. PCR amplified products were analysed by
Southern blotting and the hybridisation signals from gastric
cancers were compared with that from placenta. As shown in
Figure 3, only the sample from D.T. had an increased level
of c-erbB-2 mRNA. Relative amounts of c-erbB-2 mRNA
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Figure 1 Southern analysis of c-erbB-2 a, and P-actin b mRNA RT-PCR products from serial dilutions of human embryonic lung
fibroblasts (HEL) and MKN-7 total RNA. In Figures la and b, the left figure shows the photograph of agarose gel after
electrophoresis of each RT-PCR product and the right figure is the result of the Southern analysis. RT(-) indicates that the
sample was subjected to RT-PCR without reverse transcriptase.
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Figure 2 Plot of radioactivity of PCR products from HEL (0) and MKN-7 (0) using the intensity of the hybridisation signals in
Figure 1. The radioactivity was plotted against the concentration of total RNA as template. a shows the expression level of the
c-erbB-2 gene and b shows that of P-actin gene.
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Figure 3 Detection of c-erbB-2 mRNA expression by the RT-PCR method from gastric cancer tissue. a, Total RNA from
surgically resected gastric cancer tissue and mature placenta was diluted ranging from 5-5 to 1 fig in yeast total RNA. Each sample
was transcribed and amplified by 25 cycles of PCR, then the amplified cDNA was hybridised to the probe ERB-1 1. b,
Radioactivity of the hybridisation signal was plotted against template concentration. Results are represented as 0 = placenta,
*=M.S., E=A.H., A=E.F., OJ=S.N., A=D.T., and *=O.K.
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Table IA Comparison of c-erbB-2 gene expression between the
RT-PCR assay and the immunohistochemical assay
c-erbB-2 protein
Tumour c-erbB-2 P-actin c-erbB-2/P-actin immunoreactivity
M.S. 0.24a 6.89a 0.03b c
A.H. 0.45 25.0 0.02
E.F. 1.00 6.90 0.14
S.N. 0.67 4.26 0.16
D.T. 97.1 4.26 22.8 + +
O.K. 1.62 1.90 0.85
aTherelativeamountratioofPCRproductsinclinicalsamples tothat
in placenta was calculated with a curve in which radioactivities ofPCR
products were plotted against total RNA as template, as presented in
Figure 3b for c-erbB-2. 'The relative amounts ofc-erbB-2 mRNA were
standardised by that ofP-actin as aninternal control. cc-erbB-2 protein
immunoreactivity was classified into three groups (-, no staining; +,
weak staining; + +, strong staining).
were standardised by that ofP-actin mRNA as internal cont-
rol. The c-erbB-2 mRNA overexpression in the case of D.T.
was estimated to be 22.8-fold to placenta (Table IA).
Third, using a polyclonal antibody that is monospecific for
the c-erbB-2 oncogene product, an immunohistochemical
study on formalin-fixed paraffin-embedded tissue of these six
gastric cancers was done for detecting the expression of
c-erbB-2 protein. Among six cases, intense reactivity to this
antibody was observed only in the case of D.T. (Table IA).
More 19 (cases) of surgically resected gastric cancer including
one early cancer were examined expression level of c-erbB-2
mRNA by using RT-PCR assay and immunohistochemical
assay (Table IB). Overexpression of a 1.7 to 22.8 fold c-erbB-
2 mRNA to placenta was found in four (16%) of 25 gastric
cancers, while c-erbB-2 oncoprotein expression was found in
only three cases by immunohistochemical assay. It seems that
detection of c-erbB-2 gene products by using immunohisto-
chemical assay is limited to a case in which the oncoprotein
is expressed over about 2-fold to placenta.
Table IB Comparison of c-erbB-2 gene expression between the
RT-PCR assay and the immunohistochemical assay
Tumour c-erbB-2/P-actin c-erbB-2 protein immunoreactivity
1 2.25a + b
2 0.15 -
3 0.10 -
4 0.24 -
5 0.08 -
6 0.11 -
7 0.08 -
8 0.02 -
9 0.52 -
10 1.75 -
11 0.62 -
12 0.04 -
13 0.10 -
14 0.03 -
15 0.04 -
16 0.02 -
17 0.52 -
18 0.25 -
19 14.1 + +
'Therelative amountsofc-erbB-2 mRNAwerestandarised bythatof
P-actin as an internal control. bc-erbB-2 protein immunoreactivity was
classified into three groups (-, no staining; +, weak staining; + +,
strong staining).
In this study, the RT-PCR assay was sensitive and quanti-
tative enough for analysis of gene expression from a small
amount of total RNA. Also, the expression level of c-erbB-2
was consistent with the results of immunohistochemical
examination. This technique may be useful in examining the
expression of c-erbB-2 gene when the usual analysis is not
possible for lack of sufficient tumour tissue. The analysis of
the activated oncogenes using this RT-PCR assay may be a
good approach to elucidate the basic role of oncogenes in
malignant transformation.
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